Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis
This study assessed the real-world efficacy of vedolizumab, ustekinumab and tofacitinib as second-line therapies in patients with ulcerative colitis who were previously exposed to a TNF inhibitor.Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
More News: Drugs & Pharmacology | Gastroenterology | Health | Inflammatory Bowel Disease | Stelara | Study | Ulcerative Colitis